Richard R Caradonna

Suggest Changes
Learn More
BACKGROUND Postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors (AIs) are at risk for accelerated bone loss and subsequent fractures. The ongoing Zometa-Femara Adjuvant(More)
  • 1